sphingolipid.com

04 / DISEASE BIOCHEMISTRY

Sphingolipidoses: enzymes and accumulated lipids

Compare the biochemical defects in Gaucher, Fabry, Tay-Sachs, Krabbe, Farber, metachromatic leukodystrophy, and acid sphingomyelinase deficiency.

Last updated Educational reference

Prepared with AI assistance · Edited by Richard Vaughn.

When lysosomal degradation is impaired

Sphingolipidoses are inherited disorders involving abnormal sphingolipid degradation or handling, classically within lysosomes. Complex lipids are degraded through ordered reactions, so loss of a required enzyme can lead to accumulation of its substrate and related metabolites. Lipid-binding activator proteins and trafficking machinery can also be essential. The accumulated material and the affected tissues vary with the biochemical defect.

The table summarizes major biochemical associations rather than every stored metabolite, genetic variant, or clinical presentation. Residual enzyme activity and secondary effects can change the phenotype. Similar-sounding disease names do not always indicate the same mechanism, and an enzyme name in this table should not be used to interpret an individual's symptoms or test results.

Major disorders and their biochemical blocks

Principal deficiencies and storage substrates
DiseaseDeficient enzyme or proteinPrincipal accumulated lipids
Sandhoff diseaseβ-Hexosaminidase A and B; shared β-subunit defect (HEXB)GM2 ganglioside and neutral glycosphingolipids, including globoside
GM1 gangliosidosisLysosomal β-galactosidase (GLB1)GM1 ganglioside
Gaucher diseaseAcid β-glucosidase / glucocerebrosidase (GBA1)Glucosylceramide and glucosylsphingosine
Acid sphingomyelinase deficiency (historical Niemann–Pick A/B)Acid sphingomyelinase (SMPD1)Sphingomyelin
Fabry diseaseα-Galactosidase A (GLA)Globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3)
Tay–Sachs diseaseβ-Hexosaminidase A, α-subunit defect (HEXA)GM2 ganglioside
Krabbe diseaseGalactosylceramidase (GALC)Galactosylceramide in some cells; galactosylsphingosine (psychosine), an important toxic metabolite
Metachromatic leukodystrophyUsually arylsulfatase A (ARSA); rare saposin B deficiency produces a related defectSulfatides and related metabolites
Farber diseaseAcid ceramidase (ASAH1)Ceramide
Niemann–Pick type CNPC1 or NPC2 lipid-trafficking proteins; not a primary sphingomyelinase deficiencyUnesterified cholesterol and multiple sphingolipids, including glycosphingolipids

Why the Niemann–Pick distinction matters

Historical Niemann–Pick types A and B are associated with acid sphingomyelinase deficiency. These conditions are now often described within the acid sphingomyelinase deficiency spectrum. The primary biochemical block is hydrolysis of sphingomyelin in the lysosomal pathway. Linking the enzyme to its substrate makes this relationship straightforward.

Niemann–Pick type C instead involves NPC1 or NPC2, proteins required for normal intracellular lipid trafficking. Cholesterol and sphingolipid abnormalities arise in that different setting. Listing type C under acid sphingomyelinase deficiency would therefore be incorrect, even though the historical names share Niemann–Pick. It is included separately here to prevent that common confusion rather than to imply that every classification system places it in the same subgroup.

Storage is more complex than one lipid

A block in degradation can alter several connected pathways. Deacylated derivatives, including glucosylsphingosine and psychosine, are important examples of why naming only a complex storage lipid can be incomplete. In Krabbe disease, psychosine is especially relevant to injury of myelin-forming cells. Additional stored metabolites and cellular responses also contribute to tissue injury.

The membrane environment also affects degradation. Hydrolases must access substrates embedded in membranes, and activator proteins help make that possible. Rare saposin deficiencies and GM2 activator deficiency illustrate how impaired substrate presentation can mimic parts of an enzyme-deficiency phenotype. A complete biochemical interpretation requires attention to the entire degradative system, not just the concentration of one protein.

Genes, enzymes, and inheritance

Gene symbols identify the molecular source of a defect, while enzyme names describe the affected reaction. Keeping the two separate helps explain why HEXA and HEXB variants can cause different GM2 gangliosidoses. It also helps avoid equating a low result in one enzyme assay with a complete genetic diagnosis. The table links genetic names to biochemical reactions.

Many classical sphingolipidoses follow autosomal recessive inheritance, but Fabry disease is X-linked. Females with a pathogenic GLA variant can also have clinically important disease; describing them as always unaffected carriers is inaccurate. Clinical severity can vary within a named disorder, and biochemical classification alone does not determine an individual's prognosis.

Use the pathway to learn the disorders

Start with the lipid substrate, identify the bond that must be cleaved, and then locate the enzyme in the degradative sequence. Glucocerebrosidase removes glucose from glucosylceramide; acid sphingomyelinase releases phosphocholine from sphingomyelin; acid ceramidase cleaves ceramide's amide bond. This reaction-based approach connects the table to chemistry rather than a list of disconnected names.

The metabolism map gives the broader network, and the individual guides to glycosphingolipids and gangliosides define the substrates. For personal health questions or interpretation of test results, seek an appropriately qualified healthcare professional.

References

Sources for further reading and verification. The update date records page revisions. No independent scientific peer review is claimed.

  1. Schnaar RL, Sandhoff R, Tiemeyer M, Kinoshita T. Glycosphingolipids. In: Essentials of Glycobiology. 4th ed. Cold Spring Harbor Laboratory Press; 2022. Chapter 11.
  2. MedlinePlus Genetics. Niemann-Pick disease. U.S. National Library of Medicine. Accessed October 31, 2026.
  3. MedlinePlus Genetics. Krabbe disease. U.S. National Library of Medicine. Accessed October 31, 2026.
  4. MedlinePlus Genetics. Fabry disease. U.S. National Library of Medicine. Accessed October 31, 2026.
  5. MedlinePlus Genetics. Farber lipogranulomatosis. U.S. National Library of Medicine. Accessed October 31, 2026.
  6. MedlinePlus Genetics. Metachromatic leukodystrophy. U.S. National Library of Medicine. Accessed October 31, 2026.
  7. GeneReviews. Sandhoff Disease. University of Washington, Seattle; NCBI Bookshelf. Accessed November 1, 2026.
  8. GeneReviews. GLB1-Related Disorders. University of Washington, Seattle; NCBI Bookshelf. Accessed November 1, 2026.